Boston Birth Cohort Study Associates Maternal Folate Deficiency and Lack of Multivitamins with Accelerated Epigenetic Aging

An analysis of 742 mothers demonstrates that low maternal plasma folate and lack of prenatal multivitamin use are significantly associated with accelerated biological aging at delivery, highlighting the role of one-carbon nutrition in modulating epigenetic clocks.

Researchers analyzed clinical data from 742 mothers enrolled in the Boston Birth Cohort (1998–2013) to evaluate the impact of maternal nutrition and dietary patterns on biological aging.

Biological aging was assessed at delivery using Epigenetic Age Acceleration (EAA), defined as the difference between the Levine DNA methylation-based epigenetic clock measure and chronological age.

The study cohort had a median chronological age of 28 years (interquartile range, 23–33) and a median epigenetic age of 30 years (interquartile range, 23–36), with 66% of participants identifying as non-Hispanic Black.

Women in the lowest quartile of plasma folate exhibited significantly faster EAA compared to those with higher folate levels (β = 1.36; 95% CI, 0.35, 2.36).

Mothers who did not take prenatal multivitamins also exhibited accelerated biological aging (β = 1.59; 95% CI, 0.01, 3.17) compared to those who did.

An additive detrimental effect on biological aging was observed when low folate was combined with low Mediterranean diet adherence and elevated plasma homocysteine.

The research identifies pregnancy as a physiological stress test where maternal biological aging can be actively modulated by nutritional status and dietary interventions.

It strengthens the mechanistic link between one-carbon metabolism (specifically folate, vitamin B12, and homocysteine pathways) and DNA methylation patterns that govern biological aging metrics.

By demonstrating that dietary choices and basic supplementation correlate with reduced epigenetic age acceleration, the study highlights a accessible, low-cost therapeutic pathway to mitigate biological aging in large populations.

This study reinforces the commercial validity of utilizing DNA methylation-based epigenetic clocks as surrogate endpoints for evaluating lifestyle, dietary, and nutraceutical interventions.

Companies developing personalized wellness and longevity diagnostics may increasingly integrate one-carbon metabolic panels (folate, B12, homocysteine) alongside epigenetic clock testing to deliver targeted intervention recommendations.

The confirmation of additive benefits from combining high folate, multivitamin use, and Mediterranean diet adherence could drive consumer and clinical preference toward validated, high-potency longevity-focused nutraceutical formulations.

Prospective, randomized clinical trials designed to determine whether targeted methyl-donor supplementation can directly arrest or reverse epigenetic age acceleration in pregnant women and other clinical cohorts.